BioSpace News Archive

Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the first quarter ended March 31, 2022.

Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it had made equity grants to four new employees under its 2021 Inducement Plan.

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that all proposed resolutions at its Annual General Meeting of Shareholders, held today at 10:00 a.m. CEST, were duly passed.

Benjamin G. Neel, MD, PhD, director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Health and an internationally renowned expert in cell signaling and cancer biology, has been elected to the National Academy of Sciences.

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2022 on Wednesday, May 18, 2022 at 8:00am ET.

IR-Med, an innovative development-stage medical device company utilizing Infra-Red light spectroscopy and Artificial Intelligence technologies to develop non-invasive detection devices, announced the appointment of Moshe Gerber as Chief Executive Officer, effective immediately.

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, will present at the upcoming H.C. Wainwright Global Investment Conference.

BIOASIS TECHNOLOGIES INC. . (TSXV:BTI.V; OTCQB:BIOAF), (the “Company or “Bioasis”) a biopharmaceutical company developing its proprietary xB 3TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) announced today that it has entered into a research collaboration and license agreement with Neuramedy Co Ltd (“ Neuramedy ”) of Seoul, Korea.

RhoVac AB (“RhoVac”), a Swedish cancer immunotherapy company, announces today on May 10th, 2022 , that its phase IIb study in prostate cancer, BRaVac, has reached “Database Lock”.

Mirum Pharmaceuticals, Inc. announced that on May 10, 2022, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 178,000 shares of common stock and 52,677 restricted stock units to 18 new employees under Mirum’s 2020 Inducement Plan.